Kiniksa Pharmaceuticals Announces Closing of Initial Public Offering

Kiniksa Pharmaceuticals (Nasdaq:KNSA) announced today the closing of its initial public offering of 8,477,777 Class A common shares at a public offering price of $18.00 per share.

As quoted in the press release:

The gross proceeds from the offering were $152.6 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Kiniksa has granted the underwriters a 30-day option to purchase up to 1,271,666 additional Class A common shares at the initial public offering price, less underwriting discounts and commissions. All of the Class A common shares were offered by Kiniksa. The shares began trading on the Nasdaq Global Select Market on May 24, 2018 under the ticker symbol “KNSA.”

Goldman Sachs & Co. LLC and J.P. Morgan Securities, LLC acted as joint book-running managers for the offering. JMP Securities LLC and Wedbush Securities Inc. acted as co-managers for the offering.

Click here to read the full press release.